Simtriyo (centanafadine hydrochloride)

Where it stands

Simtriyo (centanafadine hydrochloride) is approved in the US. The records show an FDA approval on 2026-07-24 for Otsuka Pharmaceutical Co Ltd under NDA218145. The product is a new medicine in an extended-release capsule formulation.

The records do not state the therapeutic area or the approved indication, so this analysis cannot describe the patient population, dosing or labelled use. The CHMP opinion date is also blank. The only region recorded is the US, and the records contain nothing on EU or other ex-US regulatory status.

Regulatory pathway and designations

The product was reviewed through a New Drug Application (NDA218145) and carries two designations: New molecular entity (NME) and Priority review. NME status means the active moiety had not previously been approved by FDA. Priority review is an FDA review-clock designation, given to applications that FDA judges could offer a significant improvement in the treatment, diagnosis or prevention of a serious condition. It carries a shorter target review timeline than standard review.

The records do not say whether other expedited programs (such as Fast Track or Breakthrough Therapy) applied, and they give no submission date, PDUFA goal date or advisory committee history. They also do not give the evidence base for approval. We therefore cannot say how the review timeline compared with the goal date or what pivotal data supported the decision.

Because the record is a US FDA approval, there is no CHMP opinion to assess. A European Medicines Agency pathway would be a separate procedure and is not documented here.

Safety and pharmacovigilance

The records contain no safety information. They do not mention a boxed warning, contraindications, a REMS, postmarketing requirements or commitments, or any adverse-event data. We cannot characterise the benefit-risk profile or the label's safety language.

As a general point, an NME enters the market with a limited exposure database. Postmarketing surveillance (spontaneous adverse-event reporting, periodic safety reporting and any FDA-required studies) therefore carries particular weight in the first years after approval. Whether any specific measures were imposed for Simtriyo is not stated in the records.

What to watch

The first priority is the full FDA approval documentation: the prescribing information, approval letter and review documents. These would confirm the indication, dosing, warnings and any postmarketing requirements. They would also clarify the therapeutic context, which the records leave blank.

Other points to follow are Otsuka's launch plans and communications, and any updates to the label or safety communications after launch. Any filings outside the US would also matter, but none are recorded here, and none should be assumed.